Discovery of a Novel, Integrated Combination Peptide Therapeutic Targeting Angiog
Discovery of a Novel, Integrated Combination Peptide Therapeutic Targeting Angiog
批准号:
7481536
负责人:
PAUL H BESSETTE
金额:
$20.8万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-02 至 2010-02-28
关键词:
AddressAdoptedAdverse effectsAffinityBRAF geneBindingBiologicalBiological AssayBloodCancer ModelCapitalCarrier ProteinsCell SurvivalChemicalsCleaved cellClinicClinicalClinical TrialsCollaborationsCommitConsensusConsensus SequenceCultured CellsDevelopmentDiagnostic ReagentDiseaseDisorder by SiteDoseDrug Delivery SystemsEndopeptidasesEngineeringEnsureEscherichia coliExhibitsFGFR1 geneFaceFibroblast Growth FactorFibroblast Growth Factor 2FundingGelatinase BGenerationsGoalsGrowthHomologous GeneHourHuman GenomeHydrolysisImmunoglobulin GIn VitroIndividualIndustryInflammatoryIntellectual PropertyInterleukin-6InterruptionKineticsLaboratoriesLegal patentLibrariesLigandsMalignant NeoplasmsMarketingMatrix MetalloproteinasesMeasurementMeasuresMediatingMedicineMethodsMolecularMusNIH 3T3 CellsNatureNexavarNormal tissue morphologyPDGFRB genePGF genePan GenusPathway interactionsPatientsPeptide HydrolasesPeptidesPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePhasePhosphorylationPhysiciansPlacental Growth FactorPlasmaPlatelet-Derived Growth FactorProblem SolvingProcessPropertyProtease InhibitorProteinsPublic HealthPurposeR BinderRandomizedRangeRateRelative (related person)Renal clearance functionResearchRiceRodentScreening procedureSecureSerumSerum ProteinsSignal PathwaySignal TransductionSiteSpecificityStructureSurface Plasmon ResonanceSutentSystemTechnologyTestingTherapeuticToxic effectTreatment EfficacyTreatment ProtocolsTyrosine Kinase InhibitorValidationVascular Endothelial Growth Factor ReceptorVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth FactorsVisionXenograft procedureangiogenesisassay developmentbasebiological researchcancer cellcytokinedesigndrug discoveryimmunogenicityimprovedin vivoinhibitor/antagonistkinase inhibitornanosystemsnovelnovel strategiesoncologypre-clinicalpre-clinical researchprogramsprotein aminoacid sequencereceptorresearch clinical testingresponsescaffoldsmall moleculesuccesssynergismtherapeutic targettrendtumor
中文摘要
描述(由申请人提供):鉴于疾病中涉及的分子网络的复杂性,单个过程的中断通常会产生不足的治疗反应。尽管这一事实已被广泛承认,但如何克服这一问题尚不清楚。对于患者(和医生)来说,通过小分子组合的多种途径(联合治疗)的前景由于不希望出现的副作用和复杂的给药方案而变得复杂,对于行业来说,由于昂贵的治疗发现、开发和批准路径。随着最近多受体酪氨酸激酶抑制剂如索坦(PDGFR和VEGFR)和多吉伐(BRAF和VEGFR)的批准,以及临床开发中过多的泛激酶抑制剂(Zimmerman, 2007),多靶点治疗的益处在癌症中变得尤为明显。这种趋势并不令人惊讶,因为癌细胞具有利用替代信号通路来获得生长优势和细胞存活的能力,这一过程甚至可以通过使用选择性靶向药物来促进。然而,单一化合物,多靶点的方法充满了挑战;许多目标需要独特的化学物质才能有效靶向,一种药物对每个目标的最佳效力难以捉摸,非选择性是常见的。基于上述所有原因,使用高度特异性抑制剂靶向多种途径的新策略代表了一种有吸引力的治疗选择,并为正在进行的发现工作提供了强有力的理由。在CytomX,我们打算展示一种发现和组装位点特异性多靶点肽疗法的新方法,而不是所谓的肮脏的小分子方法。如果成功,这第一代综合多肽疗法将适用于许多靶点和临床问题。在我们的实验室中,我们拥有独特的专业知识,可以发现高亲和力,高特异性的肽和蛋白酶的动力学最佳肽底物。这些能力中的每一个都已经成功地瞄准了潜在的高价值治疗靶点。在这项研究中,我们将结合这些技术,基于细菌展示文库的迭代筛选,开发和测试第一个针对癌症的多靶向肽治疗。生物学研究的一个共同目标是发现更好、更安全的药物。许多方法正在被用来解决这个问题,从专门的药物递送纳米系统,到多靶向小分子,再到直接靶向人类基因组。公共卫生相关性:我们计划运用我们在肽发现方面的专业知识来解决这一全球性问题,并开发一种在疾病部位比在正常组织中更活跃的药物,并且在疾病过程中针对多个参与者。我们的目标是使这种方法足够普遍,可以用于许多不同的疾病状态,但我们目前的研究重点是血管生成领域。
英文摘要
DESCRIPTION (provided by applicant): Given the complexity of molecular networks involved in disease, the interruption of a single process often yields an insufficient therapeutic response. Although this fact is widely recognized, it is not clear how to overcome the problem. The prospect of targeting multiple pathways with a combination of small molecules (co-therapy) is complicated for the patient (and physician) by undesired side effect profiles and complicated dosing regimens and for the industry by a costly therapeutic discovery, development and approval path. The benefits of multi-target therapeutics are becoming particularly evident in cancer, with the recent approval of multi-receptor tyrosine kinase inhibitors such as sutent (PDGFR and VEGFR) and nexavar (BRAF and VEGFR) and with the plethora of pan-kinase inhibitors in clinical development (Zimmerman, 2007). This trend is not surprising, given that cancer cells possess the ability to utilize alternative signaling pathways for growth advantage and cell survival, a process that may even be facilitated by the use of selective targeted agents. Yet, the single compound, multi-targeting approach is laden with challenges; many targets require unique chemical matter for effective targeting, optimal potency at each target is elusive with one agent and nonselectivity is common. For all of the reasons stated above, novel strategies that target multiple pathways with highly specific inhibitors represent an attractive therapeutic alternative and provide a strong rationale for ongoing discovery efforts. At CytomX, instead of the so-called }dirty}, small molecule approach, we intend to demonstrate a new method for the discovery and assembly of site-specific multi-target peptide therapeutics. If successful, this first-generation integrated peptide therapeutic will be applicable to many targets and clinical problems. Within our laboratory resides unique expertise for the discovery of high affinity, high specificity peptides and kinetically-optimal peptide substrates for proteases. Each of these capabilities alone has been successful in the targeting of potential high value therapeutic targets. In this research, we will combine these technologies, both based on the iterative screening of bacterial display libraries, to develop and test the first site-directed, multi-targeted peptide therapeutic for cancer. A common goal in biological research is the discovery of better and safer medicines. Many approaches are being taken to solve this problem, ranging from specialized drug delivery nano-systems, to multi-targeted small molecules to direct targeting of the human genome. PUBLIC HEALTH RELEVANCE: we plan to apply our expertise in peptide discovery to address this world-wide issue and to develop a type of drug which is more active at the site of disease than it is in normal tissues and which targets more than one player in the disease process. Our goal is to make this approach general enough to be used for many different disease states but our research emphasis is currently in the field of angiogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金